Udiliv Uses

Is this medication very expensive?

 No   Yes 

• Udiliv indications
• Uses of Udiliv in details
• Udiliv description
• Udiliv dosage
• Udiliv interactions
• Udiliv side effects
• Udiliv contraindications

Udiliv indications

Hypertension:

Lisinopril is indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents.

Heart Failure

lisinopril is indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis.

Acute Myocardial Infarction

Lisinopril is indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta blockers.

Uses of Udiliv in details

Ursodiol is a bile acid used to dissolve gallstones in patients who do not want surgery or cannot have surgery to remove gallstones. Ursodiol is also used to prevent the formation of gallstones in overweight patients who are undergoing rapid weight loss.

Udiliv description

Udiliv is a bile acid which is physiologically synthesized in the human liver and is also formed by bacteria in the large intestine. It is present in human bile making up 1.4-4% of the biliary bile acids. Udiliv is an epimer of chenodeoxycholic acid; it differs from this bile acid only in the configuration of the hydroxyl group in the C7-position.

Udiliv dosage

Capsule: Cholestatic Liver Disease and Dissolution of Cholesterol Gallstones: Approximately 10 mg/kg body weight/day equivalent to: Up to 60 kg: 2 capsules; up to 80 kg: 3 capsules; up to 100 kg: 4 capsules; >100 kg: 5 capsules.

Treatment of Biliary Reflux Gastritis: 1 capsule daily.

Symptomatic Treatment of Primary Biliary Cirrhosis: The daily dose depends on the body weight of the patient and lies between 2 and 6 capsules (approximately 10-15 mg/kg body weight).

The following method of taking of the capsules is recommended: See table 1.

Film-Coated Tablet: There are no age restrictions on the use of Udiliv film-coated tablet. For patients weighing <47 kg or patients who are unable to swallow Udiliv film-coated tablet 500 mg, Udiliv capsules are available.

The following daily dose is recommended for the various

Indications: Dissolution of Cholesterol Gallstones: Approximately Udiliv 10 mg/kg body weight, equivalent to: Up to 60 kg: 1 film-coated tablet, 61-80 kg: 1½ film-coated tablet, 81-100 kg: 2 film-coated tablet, >100 kg: 2½ film-coated tablet.

The film-coated tablets should be swallowed whole with some liquid in the evening at bedtime. They must be taken regularly.

The time required for the dissolution of gallstones is generally 6-24 months. If there is no reduction in the size of the gallstones after 12 months, the therapy should not be continued.

The success of the treatment should be checked by means of ultrasound or x-ray examination every 6 months. At the follow-up examinations, a check should be made to see whether calcification of the stones has occurred in the meantime. Should this be the case, the treatment must be ended.

Symptomatic Treatment of Primary Biliary Cirrhosis (PBC): The daily dose depends on body weight and ranges from 1½ to 3½ film-coated tablets (Udiliv 14±2 mg/kg of body weight). For the first 3 months of treatment, Udiliv film-coated tablet should be taken divided over the day. When the liver function parameters improve, the daily dose may be taken once daily in the evening.

The film-coated tablets should be swallowed whole with some liquid. They must be taken regularly.

The use of Udiliv film-coated tablet in primary biliary cirrhosis may be continued indefinitely.

In patients with primary biliary cirrhosis, in rare cases, the clinical symptoms may worsen at the beginning of treatment eg, the itching may increase. In this event, therapy should first be continued with ½ an Udiliv film-coated tablet 500 mg or 1 Udiliv capsule (containing Udiliv 250 mg) daily and the dose then gradually increased (weekly increase of the daily dose by ½ a film-coated tablet or 1 Udiliv capsule) until the dose indicated in the respective dosage regimen is reached again.

Udiliv interactions

Udiliv should not be administered concomitantly with cholestyramine, colestipol or antacids containing aluminum hydroxide and/or smectite (aluminum oxide), because these preparations bind Udiliv in the intestine and thereby inhibits its absorption and efficacy. Should the use of a preparation containing one of these active ingredients concomitantly be necessary, it must be taken at least 2 hrs before or after Udiliv.

Udiliv can increase the absorption of ciclosporin from the intestine. In patients receiving ciclosporin treatment, blood concentrations of this substance should therefore be checked by physician and the ciclosporin dose adjusted if necessary.

In isolated cases, Udiliv can reduce the absorption of ciprofloxacin.

Film-Coated Tablet: Udiliv has been shown to reduce peak plasma concentrations (C_max) and area under the curve (AUC) of the calcium antagonist nitrendipine.

An interaction with a reduction of the therapeutic effects of dapsone was also reported.

These observations, together with in vitro findings could indicate a potential for Udiliv to induce cytochrome P450 (CYP450) 3A enzymes. Controlled clinical studies have shown, however, that Udiliv does not have a relevant inductive effect on CYP450 3A enzymes.

Estrogenic hormones and blood cholesterol-lowering agents eg, clofibrate may increase biliary lithiasis, which is a counter-effect to Udiliv used for dissolution of gallstones.

Udiliv side effects

Udiliv is generally well-tolerated. It may cause nausea, vomiting and other gastrointestinal disturbances but diarrhea is reported to occur less frequently than with chenodeoxycholic acid. Increased liver enzyme values are also less likely. Pruritus may occur. Other adverse effect reactions are headache, insomnia, bronchitis, upper respiratory tract infection, arthralgia, myalgia.

Udiliv contraindications

Hypersensitivity to Udiliv or to any of the excipients of Udiliv.

Patients with complete obstruction of biliary tract (choleretic actions may aggravate the symptoms), fulminant hepatitis, radiopaque calcifying cholelith, nonfunctioning cholecyst or acute cholecystitis, renal disease, gastric ulcers (acute gastroduodenal ulcers), colitis or enteritis eg, Crohn's disease.

Use in pregnancy: Do not administer to pregnant women or women suspected of being pregnant.

Use in children: Do not administer to pediatric patients.

Active ingredient matches for Udiliv:

Ursodeoxycholic Acid in India.

References

1. DailyMed. "URSODIOL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubChem. "URSODEOXYCHOLIC ACID". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
3. DrugBank. "URSODEOXYCHOLIC ACID". http://www.drugbank.ca/drugs/DB01586 (accessed September 17, 2018).

Reviews

User reports

Consumer reviews

Information checked by Dr. Sachin Kumar, MD Pharmacology